Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

What to Know from the FDA’s End of August Activity

ByZachary Zubulake

August 28th 2026

PharmTech Weekly Roundup—August 28, 2026

BySusan Haigney

August 28th 2026

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

ByRobert Dream,Susan Haigney

August 27th 2026

Strategies to Maximize Stability of Emerging Biologics

ByGary Watts

August 27th 2026

FDA-approved RASONQUE (daraxonrasib) tablets mark the first broad RAS-targeted therapy for metastatic pancreatic cancer treatment.

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

ByZachary Zubulake

August 26th 2026

Lessons Learned Accelerate Vaccine Development

Articles in this issue

Related Content

What to Know from the FDA’s End of August Activity

PharmTech Weekly Roundup—August 28, 2026

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

Strategies to Maximize Stability of Emerging Biologics

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

Trending on Pharmaceutical Technology

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe

What to Know from the FDA’s End of August Activity

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

Pharma's Next AI Problem Is Authority